311 related articles for article (PubMed ID: 9085044)
21. Pentagastrin gastroprotection against acid is related to H2 receptor activation but not acid secretion.
Tanaka S; Akiba Y; Kaunitz JD
Gut; 1998 Sep; 43(3):334-41. PubMed ID: 9863477
[TBL] [Abstract][Full Text] [Related]
22. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K
J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
24. FR145715, a novel histamine H2 receptor antagonist, with specific anti-Helicobacter pylori activities.
Ishikawa H; Ito H; Higaki M; Higaki M; Matsumoto Y; Kamimura T; Katsura Y; Tomishi T; Inoue Y; Takasugi H; Tomoi M; Krakowka S; Yoshida K
Eur J Pharmacol; 1999 Aug; 378(3):299-310. PubMed ID: 10493106
[TBL] [Abstract][Full Text] [Related]
25. Gastric antisecretory and antiulcer activity of oxytocin in rats and guinea pigs.
Asad M; Shewade DG; Koumaravelou K; Abraham BK; Vasu S; Ramaswamy S
Life Sci; 2001 Nov; 70(1):17-24. PubMed ID: 11764003
[TBL] [Abstract][Full Text] [Related]
26. Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Drozdowicz D; Kwiecieñ S; Pajdo R; Bielanski W; Hahn EG
Eur J Pharmacol; 2000 Jun; 398(1):147-58. PubMed ID: 10856459
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
Kim KB; Chang MS; Chung YK; Sohn SK; Kim SG; Choi WS
J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
[TBL] [Abstract][Full Text] [Related]
28. Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
Parsons ME; Rushant B; Rasmussen TC; Leach C; Ife RJ; Postius S; Pope AJ
Biochem Pharmacol; 1995 Nov; 50(10):1551-6. PubMed ID: 7503756
[TBL] [Abstract][Full Text] [Related]
29. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats.
Inatomi N; Nagaya H; Takami K; Shino A; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):437-51. PubMed ID: 1886289
[TBL] [Abstract][Full Text] [Related]
30. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
31. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
[TBL] [Abstract][Full Text] [Related]
32. JB-9322, a new selective histamine H2-receptor antagonist with potent gastric mucosal protective properties.
Palacios B; Montero MJ; Sevilla MA; Román LS
Br J Pharmacol; 1995 May; 115(1):57-66. PubMed ID: 7647984
[TBL] [Abstract][Full Text] [Related]
33. Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate.
Coruzzi G; Coppelli G; Frati P; Bertaccini G
Pharmacol Res; 1998 Dec; 38(6):469-73. PubMed ID: 9990656
[TBL] [Abstract][Full Text] [Related]
34. Effects of a new histamine H2-receptor antagonist, Z-300, on gastric secretion and gastro-duodenal lesions in rats: comparison with roxatidine.
Okabe S; Takagi K; Igata H; Kato S; Shimosako K; Yamaji Y; Seiki M
Jpn J Pharmacol; 1992 Jul; 59(3):275-89. PubMed ID: 1359178
[TBL] [Abstract][Full Text] [Related]
35. Effects of FRG-8701 on gastric acid secretion, gastric mucosal lesions by necrotizing agents and experimental gastric or duodenal ulcer in rats.
Shibata M; Yamaura T; Sekine A; Nishikawa M; Chida Y; Ohnishi H
Jpn J Pharmacol; 1990 Nov; 54(3):277-85. PubMed ID: 1982548
[TBL] [Abstract][Full Text] [Related]
36. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Nagaya H; Inatomi N; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
[TBL] [Abstract][Full Text] [Related]
37. The effect of the new H2-receptor antagonist mifentidine on gastric secretion, gastric emptying and experimental gastric and duodenal ulcers in the rat: comparison with cimetidine and ranitidine.
Scarpignato C; Tangwa M; Tramacere R; Del Soldato P
Digestion; 1986; 33(1):7-16. PubMed ID: 2866139
[TBL] [Abstract][Full Text] [Related]
38. Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
Coruzzi G; Adami M; Bertaccini G
Gen Pharmacol; 1995 Sep; 26(5):1027-32. PubMed ID: 7557245
[TBL] [Abstract][Full Text] [Related]
39. Molecular pharmacological approaches to effects of capsaicinoids and of classical antisecretory drugs on gastric basal acid secretion and on indomethacin-induced gastric mucosal damage in human healthy subjects (mini review).
Szabó IL; Czimmer J; Szolcsányi J; Mózsik G
Curr Pharm Des; 2013; 19(1):84-9. PubMed ID: 22946903
[TBL] [Abstract][Full Text] [Related]
40. Effects of KW-5805, a new antiulcer agent, on experimental gastric and duodenal ulcers, gastric mucosal lesions by necrotizing agents and gastric acid secretion.
Kosaka N; Tanaka H; Tomaru A; Ishii A; Shuto K
Jpn J Pharmacol; 1994 Aug; 65(4):305-12. PubMed ID: 7990267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
